儿科指南

订阅

MedSci主页 / 所有栏目 / 儿科指南

氟喹诺酮类抗菌药物在儿童应用中的专家共识

2017-12-19 广东省药学会 今日药学.2017.12.

氟喹诺酮类抗菌药物儿童用药

我国临床学者对于18 岁以下的儿童能否使用氟喹诺酮类药物的问题有很大争议，因此本共识介绍氟喹诺酮类药物在儿童的药代动力学特点及安全性问题（主要集中在软骨、关节的不良反应），以及目前儿童使用喹诺酮类药物的一些情况，以期给临床指导。

中文标题：

氟喹诺酮类抗菌药物在儿童应用中的专家共识

发布机构：

广东省药学会

发布日期：

2017-12-19

简要介绍：

我国临床学者对于18 岁以下的儿童能否使用氟喹诺酮类药物的问题有很大争议，因此本共识介绍氟喹诺酮类药物在儿童的药代动力学特点及安全性问题（主要集中在软骨、关节的不良反应），以及目前儿童使用喹诺酮类药物的一些情况，以期给临床指导。

 

拓展指南：与儿童相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=氟喹诺酮类抗菌药物在儿童应用中的专家共识)] GetToolGuiderByIdResponse(projectId=1, id=29b5a1c00153e98c, title=氟喹诺酮类抗菌药物在儿童应用中的专家共识, enTitle=, guiderFrom=今日药学.2017.12., authorId=null, author=, summary=我国临床学者对于18 岁以下的儿童能否使用氟喹诺酮类药物的问题有很大争议，因此本共识介绍氟喹诺酮类药物在儿童的药代动力学特点及安全性问题（主要集中在软骨、关节的不良反应），以及目前儿童使用喹诺酮类药物的一些情况，以期给临床指导。 , cover=, journalId=null, articlesId=null, associationId=1082, associationName=广东省药学会, associationIntro=广东省药学会前身为1945年成立的广州药师公会，1951年成为中国药学会广州分会。1958年在原有基础上扩大组织，成立中国药学会广东分会，负责组织全省药学科技工作者的相关活动。1985年起，中国药学会广东分会一直挂靠在广东省食品药品监督管理局（省医药管理局）。1991年，按民政部门文件要求更名为广东省药学会。, copyright=0, guiderPublishedTime=Tue Dec 19 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>我国临床学者对于18 岁以下的儿童能否使用氟喹诺酮类药物的问题有很大争议，因此本共识介绍氟喹诺酮类药物在儿童的药代动力学特点及安全性问题（主要集中在软骨、关节的不良反应），以及目前儿童使用喹诺酮类药物的一些情况，以期给临床指导。 </P> <P> </P>拓展指南：<strong>与<font color=red>儿童</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=b8f8a1c00153507b" title="2017 AHA科学声明：儿童和青少年时期遭遇不幸和心血管代谢结局" target=_blank>2017 AHA科学声明：儿童和青少年时期遭遇不幸和心血管代谢结局</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f59701c00153a6f1" title="2017 拉丁美洲共识：儿童心肺复苏术" target=_blank>2017 拉丁美洲共识：儿童心肺复苏术</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=b7d2f1c001532edb" title="2017 ERS声明：1-23月儿童阻塞性睡眠障碍性呼吸" target=_blank>2017 ERS声明：1-23月儿童阻塞性睡眠障碍性呼吸</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a06ca1c00152916a" title="2017年美国心脏协会儿童基础生命支持及心肺复苏质量的重点更新" target=_blank>2017年美国心脏协会儿童基础生命支持及心肺复苏质量的重点更新</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=b4ca21c001528821" title="2017 新西兰儿童和青少年哮喘指南" target=_blank>2017 新西兰儿童和青少年哮喘指南</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E5%84%BF%E7%AB%A5" target=_blank>有关儿童更多指南</a></ul>, tagList=[TagDto(tagId=67373, tagName=氟喹诺酮类抗菌药物), TagDto(tagId=18586, tagName=儿童用药)], categoryList=[CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6280, appHits=307, showAppHits=0, pcHits=4824, showPcHits=2079, likes=122, shares=10, comments=8, approvalStatus=1, publishedTime=Sat Dec 30 22:41:07 CST 2017, publishedTimeString=2017-12-19, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Dec 30 22:41:07 CST 2017, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 19:24:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=氟喹诺酮类抗菌药物在儿童应用中的专家共识)])
氟喹诺酮类抗菌药物在儿童应用中的专家共识
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=278963, encodeId=6aba2e8963ad, content=国内对于儿童喹诺*类用药敬而远之.可以考虑逐渐用药?值得一看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A255C84C7CC905B7A536F1089C7CFA96/100, createdBy=526a2034359, createdName=竹颜, createdTime=Tue Jan 16 07:24:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274186, encodeId=f07a2e41861b, content=非常好的文章.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Dec 31 12:43:17 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274171, encodeId=08ae2e41719c, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sun Dec 31 11:11:44 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274115, encodeId=6a312e411565, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Dec 31 09:39:47 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274064, encodeId=fb7e2e4064cf, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Dec 31 07:46:53 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2018-01-16 竹颜

    国内对于儿童喹诺*类用药敬而远之.可以考虑逐渐用药?值得一看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=278963, encodeId=6aba2e8963ad, content=国内对于儿童喹诺*类用药敬而远之.可以考虑逐渐用药?值得一看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A255C84C7CC905B7A536F1089C7CFA96/100, createdBy=526a2034359, createdName=竹颜, createdTime=Tue Jan 16 07:24:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274186, encodeId=f07a2e41861b, content=非常好的文章.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Dec 31 12:43:17 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274171, encodeId=08ae2e41719c, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sun Dec 31 11:11:44 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274115, encodeId=6a312e411565, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Dec 31 09:39:47 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274064, encodeId=fb7e2e4064cf, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Dec 31 07:46:53 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 天涯183

    非常好的文章.学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=278963, encodeId=6aba2e8963ad, content=国内对于儿童喹诺*类用药敬而远之.可以考虑逐渐用药?值得一看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A255C84C7CC905B7A536F1089C7CFA96/100, createdBy=526a2034359, createdName=竹颜, createdTime=Tue Jan 16 07:24:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274186, encodeId=f07a2e41861b, content=非常好的文章.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Dec 31 12:43:17 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274171, encodeId=08ae2e41719c, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sun Dec 31 11:11:44 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274115, encodeId=6a312e411565, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Dec 31 09:39:47 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274064, encodeId=fb7e2e4064cf, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Dec 31 07:46:53 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 1e0e5a1fm42(暂无匿称)

    henhao

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=278963, encodeId=6aba2e8963ad, content=国内对于儿童喹诺*类用药敬而远之.可以考虑逐渐用药?值得一看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A255C84C7CC905B7A536F1089C7CFA96/100, createdBy=526a2034359, createdName=竹颜, createdTime=Tue Jan 16 07:24:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274186, encodeId=f07a2e41861b, content=非常好的文章.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Dec 31 12:43:17 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274171, encodeId=08ae2e41719c, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sun Dec 31 11:11:44 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274115, encodeId=6a312e411565, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Dec 31 09:39:47 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274064, encodeId=fb7e2e4064cf, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Dec 31 07:46:53 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 龙胆草

    学习谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=278963, encodeId=6aba2e8963ad, content=国内对于儿童喹诺*类用药敬而远之.可以考虑逐渐用药?值得一看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A255C84C7CC905B7A536F1089C7CFA96/100, createdBy=526a2034359, createdName=竹颜, createdTime=Tue Jan 16 07:24:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274186, encodeId=f07a2e41861b, content=非常好的文章.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Dec 31 12:43:17 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274171, encodeId=08ae2e41719c, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sun Dec 31 11:11:44 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274115, encodeId=6a312e411565, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Dec 31 09:39:47 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274064, encodeId=fb7e2e4064cf, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Dec 31 07:46:53 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 Y—xianghai

    学习了新知识

    0